当前位置: X-MOL 学术Neuromodulation › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
First Evaluation Switching From Ropivacaine to Highly Concentrated Bupivacaine in Intrathecal Mixtures for Cancer Pain
Neuromodulation: Technology at the Neural Interface ( IF 2.8 ) Pub Date : 2021-06-28 , DOI: 10.1111/ner.13469
Florent Bienfait 1 , Sabrina Jubier‐Hamon 1 , Valérie Seegers 2 , Yves‐Marie Pluchon 3 , Nathalie Lebrec 1 , Virginie Jaoul 1 , François Boré 1 , Thierry Delorme 1 , Julien Robert 4 , Martine Bellanger 5, 6 , Jérémy Sorrieul 4 , Denis Dupoiron 1
Affiliation  

Intrathecal drug delivery is widely used for intractable cancer pain treatment. A combination of drugs with morphine and bupivacaine is recommended in first line therapy. In France, we use ropivacaine 10 mg/mL instead of bupivacaine 5 mg/mL, the only concentration available. Bupivacaine 40 mg/mL has been available in France only since July 2020 under temporary authorization of use.

中文翻译:

首次评估从罗哌卡因改为高浓度布比卡因鞘内注射治疗癌症疼痛

鞘内给药广泛用于治疗顽固性癌痛。建议在一线治疗中联合使用吗啡和布比卡因。在法国,我们使用罗哌卡因 10 毫克/毫升,而不是布比卡因 5 毫克/毫升,这是唯一可用的浓度。布比卡因 40 mg/mL 仅在 2020 年 7 月获得临时使用授权后才在法国上市。
更新日期:2021-06-28
down
wechat
bug